Objective
to investigate whether treatment with DAPT for 3 months is non-inferior to standard 12-month DAPT in patients with ACS
Study
prospective, open-label multicentre, non-inferiority randomised study (margin 5%)
Population
patients with ACS treated with COMBO stent
Endpoints
composite all-cause death, MI, stent thrombosis, stroke TUR and bleeding at 12 months
Conclusion
3-month DAPT is non-inferior to 12-month DAPT in patients with ACS receiving a COMBO stent
de Luca et al. EuroIntervention. 2019;15:e990-8
